Compounded semaglutide is a version of the active ingredient in Ozempic and Wegovy that is mixed and prepared by a compounding pharmacy rather than manufactured by the original drugmaker, Novo Nordisk. It typically costs $200 to $400 per month, compared to the much higher list prices of the brand-name versions. But compounded semaglutide is not FDA-approved, and it comes with real safety considerations worth understanding before you fill a prescription.
How Compounding Works
Drug compounding is the practice of a pharmacist creating a customized medication for an individual patient. It has a long, legitimate history in medicine. A pharmacist might compound a drug for a child who can’t swallow a pill and needs a liquid version, or for a patient allergic to a specific dye used in the commercial product. Hospitals and clinics also use compounded drugs when an FDA-approved option isn’t medically appropriate for a particular patient.
Compounding pharmacies are also allowed to produce versions of drugs that are on the FDA’s official drug shortage list. Semaglutide injection products were in shortage from 2022 through early 2025 due to surging demand, and that shortage designation opened the door for compounding pharmacies to produce their own semaglutide. This is the main reason compounded semaglutide became so widely available through telehealth companies and online pharmacies.
How It Differs From Ozempic and Wegovy
Ozempic and Wegovy are manufactured by Novo Nordisk under strict FDA oversight. Every batch must meet the same formulation, potency, and sterility standards. The drugs go through years of clinical trials before approval, producing detailed data on how they work, what side effects they cause, and at what doses they’re safe.
Compounded semaglutide skips that entire process. It does not undergo FDA review for safety, quality, or effectiveness. Instead, compounding pharmacies are regulated primarily by state pharmacy boards, with varying levels of oversight depending on the state and the type of facility. The FDA’s 503B program authorizes certain larger compounding facilities (called outsourcing facilities) to produce drugs at scale, but even these don’t face the same manufacturing scrutiny as traditional drug manufacturers.
The practical differences can be significant. Compounded semaglutide products come in various containers, including multi-dose vials and prefilled syringes. Concentrations vary from one compounder to the next, and a single pharmacy may offer multiple concentrations. The brand-name versions, by contrast, come in standardized prefilled injection pens with fixed dosing.
The Salt Form Problem
One of the FDA’s most pointed concerns involves what compounders are actually using as their starting ingredient. The approved drugs contain the base form of semaglutide. Some compounding pharmacies have been using salt forms instead, specifically semaglutide sodium or semaglutide acetate. These are chemically different active ingredients. The FDA has stated it does not have information on whether these salts behave the same way in the body as the base form, and the agency sees no lawful basis for using them in compounding.
This matters because even small chemical differences can change how a drug is absorbed, how potent it is at a given dose, and what side effects it produces. If you’re considering compounded semaglutide, asking the pharmacy whether they use the base form or a salt form is a reasonable question.
Safety Risks and Dosing Errors
The FDA has received reports of adverse events from compounded semaglutide, including some serious enough to require hospitalization. Many of these reports appear related to dosing errors. Because compounded products come in varying concentrations and different container types, patients or providers can easily miscalculate a dose, especially when converting between milligrams and volume-based units of measurement on a syringe.
Reported adverse events include nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis, and gallstones. While some of these (particularly nausea and GI symptoms) also occur with the brand-name drugs, overdosing makes them more severe and more dangerous.
Some compounders also add extra ingredients to their semaglutide products, including vitamin B12, vitamin B6, L-carnitine, and other supplements. The safety and effectiveness of combining semaglutide with these additives has not been established through any clinical testing.
Why Pharmacies Add Vitamin B12
The most common add-in is vitamin B12, and there’s a theoretical logic behind it. Semaglutide and other GLP-1 drugs slow down how quickly your stomach empties and reduce stomach acid production. Since B12 depends on stomach acid for absorption, there’s a plausible concern that long-term semaglutide use could contribute to B12 deficiency. Injecting B12 alongside semaglutide bypasses the stomach entirely, which could help maintain adequate levels.
Some providers also suggest B12 may help with the fatigue that semaglutide can cause. But none of these potential benefits have been confirmed in clinical trials for the combination product. You’re essentially taking an untested formulation based on reasonable-sounding but unproven assumptions.
Current Legal Status
The legal landscape shifted significantly in early 2025. In February 2025, the FDA determined that the semaglutide injection shortage was resolved, meaning the manufacturer confirmed it could meet current and projected national demand. Once a drug is no longer in shortage, the legal basis for compounding copies of it narrows considerably.
To ease the transition for patients already on compounded semaglutide, the FDA set grace periods: state-licensed pharmacies compounding under Section 503A of federal law had until April 22, 2025, and outsourcing facilities under Section 503B had until May 22, 2025. These deadlines were also tied to a pending federal court case brought by the Outsourcing Facilities Association challenging the FDA’s decision.
The practical impact is that the window for legally compounding semaglutide copies has been closing. Some compounders may continue operating under court orders or by arguing their products are sufficiently different from the approved versions (for example, by offering different dosage forms or combinations). But the broad, shortage-based justification that fueled the compounded semaglutide market is no longer in place.
Cost and Insurance
Cost is the primary reason most people seek out compounded semaglutide. The average runs $250 to $350 per month, with a range of roughly $200 to $500 depending on the pharmacy and dose. Insurance does not cover it.
For comparison, brand-name Wegovy (prescribed for weight loss) is excluded from Medicare entirely, and only about 20 to 30 percent of commercial insurance plans cover it, often with copays of $100 to $300 per month and strict eligibility requirements. Ozempic (prescribed for type 2 diabetes) has broader coverage, with 70 to 80 percent of commercial plans covering it after prior authorization, and typical copays of $25 to $150 per month. Without insurance, the brand-name drugs cost significantly more than compounded versions.
How to Evaluate a Compounding Pharmacy
If you’re working with a provider who prescribes compounded semaglutide, the quality of the pharmacy matters enormously. Accreditation from the National Association of Boards of Pharmacy (NABP) is one indicator. Accredited pharmacies must demonstrate compliance with USP Chapter 797, which sets standards for sterile preparations like injectable drugs, and USP Chapter 795, which covers nonsterile compounding. These standards were updated in November 2023 and cover everything from ingredient sourcing to contamination prevention.
Questions worth asking include whether the pharmacy uses semaglutide base (not a salt form), whether it holds NABP accreditation or state-level compounding accreditation, what concentration the product comes in, and whether any additional ingredients are included. A pharmacy that can’t or won’t answer these questions clearly is one to avoid.